|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.395 AUD | +1.82% |
|
+7.31% | -3.46% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Feb. 22 | Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% | MT |
Cogstate Limited provided earnings guidance for the fiscal year 2023. Clinical Trials revenue: 1H23 expected to be consistent with 2H22. 2H23 will vary with level of sales contracts and therefore unable to be accurately forecast at this time - Healthcare revenue and segment contribution expected to be consistent with FY22.
EBIT, based on current revenue forecast, expected to be at the bottom end of the target range of 20% - 24% of revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.46% | 153M | |
| +2.56% | 42.75B | |
| +47.70% | 41.61B | |
| +11.90% | 41.34B | |
| -8.83% | 26.59B | |
| +7.11% | 25.49B | |
| -22.80% | 18.12B | |
| +30.52% | 12.24B | |
| -1.92% | 11.76B | |
| +9.32% | 11B |
COGSTATE LIMITED 
